FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950595616> ?p ?o ?g. }

• W2950595616 endingPage "288" @default.
• W2950595616 startingPage "288" @default.
• W2950595616 abstract "Background: Hydroxyurea (HU) is the recommended first line therapy in high risk polycythemia vera (PV) based on the results of PVSG protocol 08. In this prospective observational study, HU was more effective in reducing the rate of thrombotic events in 51 patients in comparison with historical controls treated with phlebotomy (PHL) alone. Since then, very few studies confirmed these results. Recently, a propensity score analysis of patients enrolled in the ECLAP trial documented superiority of HU in reducing thrombosis compared to PHL only. HU was compared to Interferon (IFN) in three recent randomized controlled trials in PV; unfortunately, primary end-point of these trials was not the reduction of vascular complications but only hematological response, which is not deemed a valid surrogate of vascular events. Aims: We performed a meta-analysis to determine the absolute risk of thrombosis, bleeding, acute myelogenous leukemia (AML) and myelofibrosis (MF) in contemporary patients (2008–2018) under HU treatment. Methods: We searched for relevant articles or abstracts in the following databases: Medline, EMBASE, clinicaltrials.gov, WHO International Clinical Trials Registry, LILACS. Sixteen out of 429 published studies reporting number of events using WHO diagnostic classification for PV, met the criteria of our study protocol (registered in PROSPERO; number CRD42018117814). Through a random effect logistic model, incidences, study heterogeneity and effects of confounders were estimated for each outcome at different follow-ups. Results: Events were collected in 3,236 PV patients, during a mean follow-up ranging from 0.3 to 12.4 years. Thrombosis: Overall major thrombosis incidence (n = 469) was about 3% per year, obtained by pooling event rates from each study. In meta-regression analysis accounting for study-specific confounders such as median age, antithrombotic therapy, cardio-vascular risk factors and history of thrombosis, a slightly lower estimate of 2.8%.was found. This rate did not change over follow-up time, as shown by a comparison between a logistic and a negative binomial model, and depended on age. Annual estimates of major thrombosis in patients with a median age of 60, 70 and 80 years were 1.6%, 3.6% and 6.8% respectively. This incidence is approximately 10-fold higher than the one estimated in the general population. Bleeding: Based on 88 events over 1,485 patients, bleeding pooled incidence was 1% per year, independently of follow-up duration and antithrombotic therapy, as shown by meta-regression. Hematological transformations and mortality: Annual rate of AML (n = 63) was fairly constant over time and the cumulative 10-year incidence was about 4% (0.4% patients/year). In contrast, rate of evolution into MF (n = 157), as predicted by meta-regression, increased steeply after 5 years of follow-up. In the 0–5/5–10 years of follow-up the average annual rate of MF evolution was 1.0% and 5.1% respectively. Mortality (n = 522) followed a similar pattern as MF. Estimates were 2.4%, 12.6% and 56.2% at 1, 5 and 10 years respectively. Summary/Conclusion: The results of this meta-analysis can be a valid reference for patient communication and counseling, and also constitute a help for sample size calculations in future comparative clinical trials adopting hard efficacy endpoints (thrombosis) in selected populations." @default.
• W2950595616 created "2019-06-27" @default.
• W2950595616 creator A5002977848 @default.
• W2950595616 creator A5014707543 @default.
• W2950595616 creator A5028356813 @default.
• W2950595616 creator A5050277803 @default.
• W2950595616 creator A5052615539 @default.
• W2950595616 creator A5054304877 @default.
• W2950595616 creator A5063850306 @default.
• W2950595616 creator A5069072959 @default.
• W2950595616 date "2019-06-01" @default.
• W2950595616 modified "2023-09-24" @default.
• W2950595616 title "PF671 RATE OF THROMBOSIS IN CONTEMPORARY PATIENTS WITH POLYCYTHEMIA VERA UNDER HYDROXYUREA REMAINS EXCEEDINGLY HIGH. RESULTS OF SYSTEMATIC REVIEW AND METANALYSIS" @default.
• W2950595616 doi "https://doi.org/10.1097/01.hs9.0000560968.14012.ef" @default.
• W2950595616 hasPublicationYear "2019" @default.
• W2950595616 type Work @default.
• W2950595616 sameAs 2950595616 @default.
• W2950595616 citedByCount "0" @default.
• W2950595616 crossrefType "journal-article" @default.
• W2950595616 hasAuthorship W2950595616A5002977848 @default.
• W2950595616 hasAuthorship W2950595616A5014707543 @default.
• W2950595616 hasAuthorship W2950595616A5028356813 @default.
• W2950595616 hasAuthorship W2950595616A5050277803 @default.
• W2950595616 hasAuthorship W2950595616A5052615539 @default.
• W2950595616 hasAuthorship W2950595616A5054304877 @default.
• W2950595616 hasAuthorship W2950595616A5063850306 @default.
• W2950595616 hasAuthorship W2950595616A5069072959 @default.
• W2950595616 hasBestOaLocation W29505956161 @default.
• W2950595616 hasConcept C120665830 @default.
• W2950595616 hasConcept C121332964 @default.
• W2950595616 hasConcept C126322002 @default.
• W2950595616 hasConcept C168563851 @default.
• W2950595616 hasConcept C2777357209 @default.
• W2950595616 hasConcept C2778837598 @default.
• W2950595616 hasConcept C2780868729 @default.
• W2950595616 hasConcept C535046627 @default.
• W2950595616 hasConcept C61511704 @default.
• W2950595616 hasConcept C71924100 @default.
• W2950595616 hasConceptScore W2950595616C120665830 @default.
• W2950595616 hasConceptScore W2950595616C121332964 @default.
• W2950595616 hasConceptScore W2950595616C126322002 @default.
• W2950595616 hasConceptScore W2950595616C168563851 @default.
• W2950595616 hasConceptScore W2950595616C2777357209 @default.
• W2950595616 hasConceptScore W2950595616C2778837598 @default.
• W2950595616 hasConceptScore W2950595616C2780868729 @default.
• W2950595616 hasConceptScore W2950595616C535046627 @default.
• W2950595616 hasConceptScore W2950595616C61511704 @default.
• W2950595616 hasConceptScore W2950595616C71924100 @default.
• W2950595616 hasIssue "S1" @default.
• W2950595616 hasLocation W29505956161 @default.
• W2950595616 hasLocation W29505956162 @default.
• W2950595616 hasOpenAccess W2950595616 @default.
• W2950595616 hasPrimaryLocation W29505956161 @default.
• W2950595616 hasRelatedWork W1978560829 @default.
• W2950595616 hasRelatedWork W1989846405 @default.
• W2950595616 hasRelatedWork W2001847124 @default.
• W2950595616 hasRelatedWork W2040000334 @default.
• W2950595616 hasRelatedWork W2057651362 @default.
• W2950595616 hasRelatedWork W2414708573 @default.
• W2950595616 hasRelatedWork W2757669833 @default.
• W2950595616 hasRelatedWork W2920828896 @default.
• W2950595616 hasRelatedWork W2991586457 @default.
• W2950595616 hasRelatedWork W2188926379 @default.
• W2950595616 hasVolume "3" @default.
• W2950595616 isParatext "false" @default.
• W2950595616 isRetracted "false" @default.
• W2950595616 magId "2950595616" @default.
• W2950595616 workType "article" @default.